CCT5 and bladder transitional cell carcinoma: Furthermore, disease-free survival (DFS) analysis showed that high CCT5 expression was a marker for poor outcomes in patients with BLCA (log-rank p = 0.037), KIRP (log-rank p = 0.035), and LIHC (log-rank p = 0.0069) (Fig. 3).